Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Bayer

Status: Completed

Conditions: Deep Vein Thrombosis; Venous Thrombosis

Treatments: Drug: Standard of care; Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Industry

Identifiers

NCT01619007

15915 (Other Identifier)

XA1102 (Other Identifier)

Details and patient eligibility

About

Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute deep vein thrombosis (DVT).

The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute DVT in routine clinical practice.

Enrollment: 5,145 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female and male patients
• Patients >= 18 years
• Patiebts with diagnosis of acute DVT and who have an indication for anticoagulation therapy for at least 12 weeks, who are willing to participate in this study and are available for follow-up

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information.

Trial design

5,145 participants in 2 patient groups

Group 1

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)

Group 2

Treatment:

Drug: Standard of care